Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with ...

The licensing deal could set the US drugmaker to vie with Eli Lilly & Co. and Novo Nordisk A/S, the current leaders in a ...

Eli Lilly and Company, UnitedHealth Group, AbbVie, Walmart, Johnson & Johnson, Natera, and Gilead Sciences are the seven Medical stocks to watch today, according to MarketBeat’s stock screener tool.

Growth and income investors who want to stay invested but shift to a more balanced approach may want to look at the Dividend ...

This was the stock's third consecutive day of gains.

The microbial fermentation technology market is experiencing significant growth, fueled by the increasing incidence of chronic diseases like cancer a ...

Looking for broad exposure to the Large Cap Value segment of the US equity market? You should consider the Invesco Large Cap Value ETF (PWV), a passively managed exchange traded fund launched on 03/03 ...

Co-Diagnostics, Inc.  (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, ...

The latest trading session saw AbbVie (ABBV) ending at $211.48, denoting a +1.17% adjustment from its last day's close. This change outpaced the S&P 500's 1.76% loss on the day. At the same time, the ...

AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...

AbbVie has signed a licensing deal with Gubra A/S to develop an obesity drug, marking the North Chicago company's first foray ...